Please provide your email address to receive an email when new articles are posted on . Etavopivat reduced the annualized vaso-occlusive crises rate vs. placebo. The agent increased hemoglobin levels, ...
SAN DIEGO — A newly approved gene therapy product for sickle cell disease, lovotibeglogene autotemcel (lovo-cel, marketed as Lyfgenia), led to durable disease remissions for up to 5 years and almost ...
Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats ...
Dr. Ya Haddy Sallah (Medicine): A 29-year-old man with sickle cell disease was admitted to this hospital because of pain in the right hip. The patient had received a diagnosis of sickle cell disease ...
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird bio” or “bluebird”) today announced the U.S. Food and Drug Administration ...
Please provide your email address to receive an email when new articles are posted on . Children with beta thalassemia achieved transfusion independence after being treated with exa-cel. Children with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results